Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Trifluoroacetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 4/20 | 0.36 |
| ▸ | ESR2 known ✓ | Q92731 | 4/20 | 0.36 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.35 |
| ▸ | HDAC3 known ✓ | O15379 | 3/20 | 0.33 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.33 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.33 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL1679512 | 0.84 | CA12 (0.55) | CA12CA1CA2GLACA3 | |
| Trifluoroacetic Acid SCHEMBL5571447 | 0.83 | CA12 (0.44) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL1679490 | 0.82 | CA12 (0.58) | CA12CA1CA2GLACA3 | |
| Trifluoroacetic Acid SCHEMBL5776611 | 0.82 | CA12 (0.58) | CA12CA1CA2GLACA3 | |
| Trifluoroacetic Acid SCHEMBL30260008 | 0.82 | CA12 (0.58) | CA12CA1CA2GLACA3 | |
| Trifluoroacetic Acid SCHEMBL25326318 | 0.82 | CA12 (0.58) | CA12CA1CA2GLACA3 | |
| Trifluoroacetic Acid SCHEMBL995275 | 0.82 | TP53 (0.30) | ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL466686 | 0.82 | CA12 (0.58) | CA12CA1CA2GLACA3 | |
| Methylphenylsulfide SCHEMBL19639862 | 0.81 | DPP4 (0.39) | CES1CYP1A2CYP2D6DPP4DPP7 | |
| Anisole SCHEMBL4623600 | 0.81 | CA4 (0.45) | CA1CA2CA4CES1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11000625-B2 | Amplified photodegradation of hydrogels and methods of producing the same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-05-11 | — | — | US | disclosed |
| US-20180361016-A1 | Amplified Photodegradation of Hydrogels and Methods of Producing the Same | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2018-12-20 | — | — | US | disclosed |
| WO-2015115924-A1 | PENTAPEPTIDES CONTAINING 3-[2-(2-QUINOLINYL)BENZOXAZOL-5-YL]ALANINE, A PHARMACEUTICAL COMPOSITION AND THEIR APPLICATION | GDANSKI UNIWERSYTET MEDYCZNY (PL) | 2015-08-06 | — | — | WO | disclosed |
| US-8936916-B2 | Polypeptides for microbial detection | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-01-20 | — | — | US | disclosed |
| EP-2250188-B1 | POLYPEPTIDES FOR MICROBIAL DETECTION | 3M INNOVATIVE PROPERTIES CO (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20130309693-A1 | POLYPEPTIDES FOR MICROBIAL DETECTION | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-11-21 | — | — | US | disclosed |
| US-8497353-B2 | Polypeptides for microbial detection | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| US-20100317050-A1 | POLYPEPTIDES FOR MICROBIAL DETECTION | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2010-12-16 | — | — | US | disclosed |
| EP-2250188-A2 | POLYPEPTIDES FOR MICROBIAL DETECTION | 3M Innovative Properties Company (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7670605-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2010-03-02 | — | — | US | disclosed |
| US-20090098083-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | UNIVERSITAT ZURICH (CH) | 2009-04-16 | — | — | US | disclosed |
| WO-2008144728-A1 | CONJUGATES WHICH BIND A BLOOD PROTEIN SUCH AS HUMAN SERUM ALBUMIN AND METHODS OF USING THE SAME IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2008-11-27 | — | — | WO | disclosed |
| US-7413739-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2008-08-19 | — | — | US | disclosed |
| US-7291673-B2 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSICHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2007-11-06 | — | — | US | disclosed |
| US-20060127352-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2006-06-15 | — | — | US | disclosed |
| US-6958212-B1 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2005-10-25 | — | — | US | disclosed |
| EP-1292709-A4 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOESS TECH HOCHSCHULE (CH) | 2004-09-22 | — | — | EP | disclosed |
| US-20030220245-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1292709-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | Eidgenössische Technische Hochschule Zürich (CH) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001092584-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | EIDGENOSSISCHE TECHNISCHE HOCHSCHULE ZURICH (CH) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060127352-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds | PAICS, COASY, LIPA | ESR1 1231/4885ESR2 2682/4885DPP4 425/4885 |
| US-20090098083-A1 | CONJUGATE ADDITION REACTIONS FOR THE CONTROLLED DELIVERY OF PHARMACEUTICALLY ACTIVE COMPOUNDS | PAICS, COASY, LIPA | ESR1 1231/4885ESR2 2682/4885DPP4 425/4885 |
| US-20030220245-A1 | Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds | PAICS, C9, LIPA | ESR1 902/4885ESR2 2335/4885DPP4 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.